A new study has confirmed that the human papillomavirus (HPV) vaccine provides strong and long-lasting protection against cervical diseases that can progress to cancer. The findings reaffirm the vaccine’s vital role in preventing one of the most common cancers affecting women worldwide.
Vaccine Shows Strong Protection in Younger Girls
According to the study, the HPV vaccine offers the greatest protection when administered to girls aged 18 years or under, with the most significant benefits observed in those vaccinated at ages 12 or 13. The results underline the importance of early immunisation to achieve the highest level of protection.
Effectiveness Sustained for Over a Decade
Building on earlier evidence, the new research confirms that the HPV vaccine remains highly effective more than 12 years after administration. The study used population health data and followed women who later attended cervical screening, demonstrating the vaccine’s lasting impact in preventing cervical pre-cancer and cancer.
Reducing Health Inequalities
Encouragingly, the study found that women from Scotland’s most deprived areas benefited the most from vaccination. This suggests that the HPV immunisation programme is helping to reduce long-standing health inequalities, particularly in communities that face higher barriers to healthcare access.
Collaboration and Publication
Public Health Scotland, in collaboration with the Universities of Strathclyde and Edinburgh, has published the research in the International Journal of Cancer.
Experts Highlight the Vaccine’s Success
Professor Kimberley Kavanagh, from Strathclyde’s Department of Mathematics and Statistics, emphasised the vaccine’s remarkable success.
“This new research highlights the long-term positive impact of Scotland’s HPV vaccination programme, especially in areas of deprivation. The earlier the vaccine is taken up, the more effective it is likely to be. When combined with regular cervical screening, it can significantly reduce cervical cancer cases,” she explained.
HPV: A Major Cause of Cervical Cancer
HPV spreads primarily through sexual contact and causes almost all cases of cervical cancer, which remains the fourth-most common cancer among women worldwide. Scotland’s routine cervical screening programme, together with the HPV immunisation programme introduced in 2008, continues to play a critical role in reducing both HPV prevalence and cervical pre-cancer development.
Routine Vaccination Through Schools
In Scotland, the HPV vaccine is routinely offered to all S1 pupils through school-based immunisation programmes. This ensures early protection and widespread coverage among adolescents before potential exposure to the virus.
Making Cervical Cancer a Rare Disease
As reported by The University of Strathclyde Press release, Dr Kirsty Roy, Consultant in Public Health at Public Health Scotland, reiterated the vaccine’s preventive power.
“Vaccination against HPV is highly effective in preventing cervical cancer. Along with regular screening for early detection and treatment, it’s possible to make cervical cancer a rare disease,” she said.
She further encouraged all S1 pupils to accept the free HPV vaccine when it is offered. She noted that Public Health Scotland continues to work closely with the Scottish Government and local health boards. The aim is to maintain strong uptake of both key prevention measures — the HPV vaccine and routine cervical screening.
Toward a Future Free from Cervical Cancer
With continued commitment to vaccination and screening, Scotland moves closer to a future where cervical cancer becomes preventable and rare. This progress will help ensure better health outcomes for generations to come.